Does cyclosporin increase lipoprotein(a) concentrations in renal transplant recipients?
Cyclosporin, the immunosuppressant of choice for renal transplant recipients, has been implicated as the cause of abnormalities in serum lipid concentrations in these patients. We have measured serum lipoprotein(a) concentrations and analysed the distribution of apoprotein(a) isoforms in 90 renal transplant recipients receiving cyclosporin and prednisolone (with or without azathioprine), 59 patients receiving azathioprine and prednisolone alone, and 146 non-hyperlipidaemic controls. Cyclosporin-treated patients had significantly higher lipoprotein(a) concentrations (median 170 [interquartile range 55-382] mg/L) than those receiving azathioprine and prednisolone (64 [10-204] mg/L, p = 0.001) or the healthy controls (94 [18-280] mg/L, p = 0.008). The difference between the azathioprine and prednisolone group and the controls was not significant. Although the time since transplantation was significantly shorter for the cyclosporin-treated group, there was no correlation between lipoprotein(a) concentration and time since transplantation (r = -0.13, p = 0.18). Apoprotein(a) phenotyping showed no significant differences in the distribution of apoprotein(a) isoforms between the treatment groups or between patient and control groups. Lipoprotein(a) concentrations are higher in renal transplant recipients treated with cyclosporin than in those maintained on azathioprine and prednisolone. The mechanisms underlying this abnormality remain to be elucidated.